Back to News
Market Impact: 0.4
CSL und Alentis geben weltweite Partnerschaft zur Entwicklung und Vermarktung von lixudebart für seltene Nieren- und Lebererkrankungen bekannt
Source: PR Newswire
Healthcare & BiotechM&A & RestructuringCompany Fundamentals
CSL and Alentis Therapeutics announced an agreement under which Alentis will receive an upfront payment of $355 million and is eligible for up to $1.2 billion in commercial milestone payments. The companies will share worldwide profits; the excerpt provides no further terms or details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
More News
- Samsung, SK Hynix shares drop as Q3 earnings loom
- CH Robinson to Buy RXO for $5.8B in Bet on AI Model
- BPCE acquires 7% stake in Spain’s Banco Sabadell
- Wells Fargo gets a bold upgrade ahead of earnings. Why the stock can play catch-up
- Brazil Election: Bolsonaro Pushes Lula to Brink as Markets Set to Rally
- SpaceX stock climbs to highest since June, returning Musk to trillionaire status
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Capital IQ Alternatives for Research and Deal Work
- Research Workflows, Report Format Selection, and Interactive Synthesis